Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

ASH 2022 Conference Coverage
J

ASH 2022 on Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia

By ASH 2022 Conference Coverage FEATURING Jorge Castillo
By ASH 2022 Conference Coverage FEATURING Jorge Castillo
62 views
December 22, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Featured Video

09:36
Johnson & Johnson

Mechanisms of Resistance in Locally Advanced or Metastatic EGFR+ NSC…

Feat. J. Heymach, M. Das
Lymphoma
12:43
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Bispecific Antibodies or CAR T-Cells for Indolent B-NHL?

Feat. C. Jacobson
05:36
Oncology Data Advisor

Phase 1/2 EPCORE NHL-2 Trial: Investigating Epcoritamab for R/R Foll…

Feat. R. Merryman
10:36
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Epcoritamab + R² Regimen and Responses in…

Feat. R. Merryman
19:42
Indy Hematology Review

Beyond Hyperviscosity: 80 Years and Counting - Treatment of Waldenst…

Feat. S. Treon
12:50
ASH 2022 Conference Coverage

ASH 2022 on Ibrutinib and Venetoclax in Previously Untreated Waldens…

Feat. J. Castillo
13:46
Dana-Farber Cancer Institute

Venetoclax in Previously Treated Waldenström Macroglobulinemia

Feat. J. Castillo